All In Biotech

Drug Trial Radar · NCT06847191

NE3107 in Adults With Neurological Symptoms of Long COVID

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 203 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

203

Actual

Start

Apr 29, 2025

Primary completion

Aug 6, 2026

Study completion Sep 2, 2026

Sponsor

Lead sponsor
BioVie Inc.Industry
Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. This study is designed as a signal-seeking proof-of-concept Phase 2 study. The primary outcome is intended for estimation and hypothesis generation rather than formal hypothesis testing. No single endpoint is designated as definitive for study success. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

Conditions

  • Long COVID

Interventions

  • NE3107Drug

    20 mg Capsule

  • PlaceboDrug

    placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in performance on the Cogstate Cognition battery*Time frame: 12 Weeks
  2. Change from Baseline in PROMIS Cognitive Function Short Form 8a (SF-8a)Time frame: 12 Weeks
  3. Change from Baseline in PROMIS Fatigue Short Form 13a (SF-13a)Time frame: 12 Weeks
  4. Change from Baseline in PROMIS Sleep Disturbance Short Form 8a (SF-8a)Time frame: 12 Weeks
  5. Change from Baseline in SF-12 Health Survey (Physical Component Scores)Time frame: 12 Weeks
  6. Change from Baseline in SF-12 Health Survey (Mental Component Scores)Time frame: 12 Weeks
  7. Change from Baseline in DePaul Symptom Questionnaire (DSQ) Post-Exertional MalaiseTime frame: 12 Weeks
  8. Composite Benefit ScoreTime frame: 12 Weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • UCSF

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Clinical Trial Site

    Jacksonville, Florida

  • Centricity Research

    Columbus, Georgia

  • Illinois Research Network University of Illinois at Chicago

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Norton Infectious Disease Institute

    Louisville, Kentucky

  • Jadestone Clinical Research

    Silver Spring, Maryland

  • Clinical Trial Site

    Farmington Hills, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Zenos Clinical Research

    Dallas, Texas

  • University of Texas health Science Center at San Antonio

    San Antonio, Texas

  • Chronicle Bio Inc.

    Park City, Utah

  • Swedish Center for Research and Innovation

    Seattle, Washington

  • West Virginia University

    Morgantown, West Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.